NCT05965024Recruiting
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
Exploration on the Value of Molecular Residual Disease Based on Circulating Tumor DNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 21 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Based on the unique patented MONOD and Methyl Titan methylation sequencing technology on lung cancer tissue and blood samples, a lung cancer MRD monitoring panel is designed. The panel is used to detect molecular residual disease of stage IB-IIIB non-small cell lung cancer patients underwent radical surgery, explore personalized analysis models, and conduct research on recurrence monitoring for non-small cell lung cancer patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 377 (estimated)
- First submitted
- 20 Jul 2023
- Start date
- 25 Oct 2023
- Primary completion date
- Aug 2026
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Diseases
- Lung cancer
- NCT number
- NCT05965024
What you commit to
- Study type: Observational
- Planned participants: 377
- From 25 Oct 2023 to the primary completion date, Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Those who have undergone neoadjuvant therapy before surgery;
- Those who have undergone a blood transfusion within 2 weeks before the surgery;
- Participants in other clinical trials within the past 30 days and have taken investigational drugs;
Other illness
- Individuals with a history of other malignant tumors within 5 years;
- Individuals with systemic inflammatory response syndrome;
- Those with serious diseases of important organs such as the heart, lungs, kidneys, and brain;
Other
- Postoperative incision margin R1 or incision margin R2;
- Due to various reasons, sampling cannot be completed, samples do not meet the requirements, or baseline samples (preoperative and postoperative plasma samples, tumor tissue samples) are incomplete;
- Researchers believe that it is not appropriate to participate in this experiment.
Who the study is looking for
- Age ≥ 18 years old, regardless of gender;
- Patients with pathological diagnosis of non-small cell lung cancer and clinical staging of stage IB-IIIB;
- Able to undergo radical surgical treatment;
- Physical condition score (ECOG) ≤1;
- The expected survival time exceeds 24 months;
- Volunteer to participate in this study and sign an informed consent form.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Pulmonary Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.